Causes of death after breast cancer diagnosis: A US population‐based analysis
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: The focus on noncancer causes of death in patients with breast cancer (BC) remains superficial. The objective of the current study was to assess and quantify causes of death after BC diagnosis. Methods: In total, 754,270 women with BC in the United States who were diagnosed during 2000 through 2015 and retrieved from the Surveillance, Epidemiology, and End Results (SEER) program were studied. Standardized mortality ratios (SMRs) for causes of death were calculated. Results: Of the included patients, 183,002 (24.3%) died during the follow‐up period. The greatest proportion of deaths (46.2%) occurred within 1 to 5 years after diagnosis. Most deaths occurred from BC itself or from other cancers, and the number of BC deaths decreased as more years passed after diagnosis. The most common noncancer causes of death within <10 years after diagnosis were heart diseases followed by cerebrovascular diseases. However, >10 years after diagnosis, the most common noncancer causes of death were heart diseases followed by Alzheimer disease. Patients had a statistically significant higher risk of death from chronic liver diseases within 5 to 10 years after diagnosis compared with the general population (SMR, 1.23; 95% CI, 1.09‐1.38) and had statistically significant higher risks of death from Alzheimer disease (SMR, 1.21; 95% CI, 1.14‐1.29) and from diseases of the heart (SMR, 1.06; 95% CI, 1.02‐1.09) >10 years after diagnosis. Conclusions: Although BC remains the most common cause of death after BC diagnosis, other non‐BC causes of death (mainly heart and cerebrovascular diseases) represent a significant number of deaths among patients with BC. These findings provide important insight into how BC survivors should be counselled regarding future health risks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010 · Cited by 17,796
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · cited 1×
“Cardiotoxicity is a recognized adverse event of the anthracyclines and HER2-directed agents.(17-19) This toxicity is dose-dependent with anthracyclines and results in the development of heart failure and cardiomyopathy.”
BackgroundPalbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164
Suicidal death within a year of a cancer diagnosis: A population‐based study
Saad, A. M., Gad, M. M., Al‐Husseini, M. J., AlKhayat, M. A., Rachid, A., Alfaar, A. S., & Hamoda, H. M. (2019) · Cancer · doi:10.1002/cncr.31876 · Cited by 117 · cited 2×
“The incidence of suicidal death has been noted to be higher among patients with cancer.(35) However, in our study, the overall BC population did not have an increased suicidal risk after cancer diagnosis.”
BackgroundResultSelf-citation
Cited by
Landscape of Immune Microenvironment Under Immune Cell Infiltration Pattern in Breast Cancer
Xu, Q., Chen, S., Hu, Y., & Huang, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.711433 · Cited by 180
Lipsyc-Sharf, M., de Bruin, E. C., Santos, K., McEwen, R., Stetson, D., Patel, A., Kirkner, G. J., Hughes, M. E., Tolaney, S. M., Partridge, A. H., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00908 · Cited by 152
“Additionally, many patients with early-stage HR1 breast cancer in the late adjuvant setting ultimately die of non–breast cancer causes including cardiovascular, cerebrovascular, and neurodegenerative diseases.(36) If MRD screening becomes part of future routine care, the decision to screen for MRD should incorporate t…”
Background
Metadata
- Authors
- Afifi, A. M., Saad, A. M., Al‐Husseini, M. J., Elmehrath, A. O., Northfelt, D. W., & Sonbol, M. B.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2019-12-16
- Volume
- 126
- Issue
- 7
- Pages
- 1559-1567
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2995087365
- Cited by
- 210
- References
- 7
- FWCI
- 6.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.